利用FATLESS方法解锁乳腺癌MRI中的rNOE-CEST对比
本研究开发了一种基于软件的全自动脂肪校正方法FATLESS,用于校正乳腺CEST MRI中脂肪伪影对rNOE信号的影响,并回顾性应用于9例乳腺癌患者和7例健康对照的7T CEST数据。结果显示,肿瘤区脂肪校正后rNOE MTR_Rex值较健康纤维腺体组织平均升高140%(P<0.001),且与Ki-67强相关(R²=0.71)。
要点
- FATLESS可校正全Z谱脂肪伪影,使肿瘤区rNOE MTR_Rex值较健康组织平均升高140%(P<0.001)。
- 脂肪校正后rNOE MTR_Rex值与肿瘤增殖标志物Ki-67呈强正相关(R²=0.71)。
- FATLESS为纯软件后处理方法,回顾性应用于7T低饱和功率(B1=0.6、0.9 μT)2D snapshot GRE CEST数据。
核心结论
- FATLESS脂肪校正方法可充分利用人乳腺CEST MRI的全部对比,脂肪校正后rNOE对比显著升高且与肿瘤增殖强相关,提示其可能作为乳腺癌无创影像生物标志物。
研究设计与样本
- 回顾性研究,纳入9例经活检证实的乳腺癌患者(平均年龄50岁±10岁)和7例健康对照(平均年龄25岁±4岁),回顾性应用FATLESS于2018年9月至2019年5月采集的7T CEST数据,采用2D snapshot GRE CEST序列,低饱和功率(B1=0.6、0.9 μT)。
关键影像表现/征象
- 脂肪校正后rNOE MTR_Rex图在体模和体内数据中得到验证,证实经FATLESS校正后独立于脂肪伪影。
- 肿瘤区脂肪校正后MTR_Rex rNOE值显著高于健康组织(平均升高140%,P<0.001)。
- 脂肪校正后MTR_Rex rNOE值与Ki-67呈强正相关(R²=0.71)。
诊断标准与关键数值
- 采用Kruskal-Wallis检验比较肿瘤与正常纤维腺体组织的MTR_Rex值,采用Pearson相关分析评估与Ki-67的相关性。
- 脂肪校正后rNOE MTR_Rex值在肿瘤区较健康组织平均升高140%(P<0.001),与Ki-67的R²=0.71。
临床应用与阅片要点
- FATLESS为纯软件后处理方法,可校正全Z谱脂肪伪影,使rNOE-CEST对比在乳腺MRI中得以准确评估。
- 脂肪校正后rNOE MTR_Rex值在肿瘤区显著高于健康纤维腺体组织,且与Ki-67强相关,提示其可能用于乳腺癌特征描述。
局限性
- FATLESS为回顾性应用,样本量较小(9例乳腺癌患者和7例健康对照)。
- 健康对照平均年龄(25岁±4岁)与乳腺癌患者(50岁±10岁)差异较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Quantitative chemical exchange saturation transfer (CEST) breast imaging is limited by pronounced fat-induced artifacts. The strongest fat artifact, appearing between [-2, -4] ppm in the Z-spectrum, directly overlaps the signal of the exchange-relayed nuclear Overhauser effect (rNOE) at around -3.5 ppm, a key biomarker for protein content and cellularity, making accurate rNOE-CEST evaluation extremely challenging. The aim of this study is to evaluate rNOE-CEST contrast corrected for fat-related artifacts using a novel, fully software-based fat correction method in breast cancer patients.
MATERIALS AND METHODS: FATLESS (Fat Attenuation Technique using Lipid signal Estimation and Simulated Saturations in postprocessing) was developed for correcting fat-related artifacts across the entire Z-spectrum in CEST MRI. The FATLESS method estimates fat signals from residual signals at the direct water saturation offset (0 ppm) while accounting for partial saturation of fat resonances. FATLESS was retrospectively applied to 7T CEST data from breast cancer patients (acquired September 2018 to May 2019). Resulting fat-corrected rNOE, amide, and guanidino MTR Rex contrast values were quantified from 2D snapshot GRE CEST with low saturation power (B 1 =0.6, 0.9 μT). Kruskal-Wallis tests and Pearson correlation analyses were used to compare MTR Rex values between tumor and normal-appearing fibroglandular tissue and assess correlations with Ki-67, a tumor proliferation marker.
RESULTS: Nine biopsy-confirmed breast cancer patients [mean age, 50 y ± 10 (SD)] and 7 healthy controls [mean age, 25 y ± 4 (SD)] were included. Fat-corrected MTR Rex rNOE maps were validated in phantom and in vivo data, confirming independence from fat artifacts using the FATLESS method. Tumor regions showed significantly higher fat-corrected MTR Rex rNOE values than healthy tissue (+140% mean increase, P <0.001). A strong positive correlation was found between fat-corrected MTR Rex rNOE values and Ki-67 ( R ² = 0.71).
CONCLUSIONS: The developed FATLESS fat correction method enables full utilization of all CEST MRI contrasts in the human breast. The observed significant rNOE contrast elevation and strong correlation with tumor proliferation highlight its potential as a non-invasive imaging biomarker for breast cancer characterization.
引用
- Boyd PS, Menshchikov P, Loi L, et al. Unlocking the rNOE-CEST Contrast for Breast Cancer MRI Using the FATLESS Approach. Invest Radiol. 2026. PMID: 40690311. doi:10.1097/RLI.0000000000001222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。